The brain on MDMA can go somewhere CBT has never been able to reach | Rachel Yehuda: Full Interview

Rachel Yehuda’s interview provides a compelling and scientifically grounded overview of PTSD and the potential of MDMA-assisted therapy. Her expertise is evident as she articulates complex neurobiological and psychological concepts in an accessible manner. The discussion on the distinction between stress and trauma is particularly insightful, highlighting the enduring nature of trauma and its impact on self-perception. Yehuda’s explanation of how MDMA facilitates therapeutic processing is nuanced, acknowledging both its benefits and limitations. She correctly notes that MDMA is not a classic psychedelic and that its mechanism differs from substances like psilocybin, which is an important distinction for clinical practice. The interview also touches on the societal and cultural factors that influence PTSD prevalence and recovery, adding depth to the analysis. However, the presentation is primarily an expert opinion rather than a systematic review of evidence. While Yehuda cites clinical trial results, she does not provide specific data or references, which limits the ability to independently verify her claims. Additionally, the recent FDA rejection of MDMA-assisted therapy for PTSD is not mentioned, which could be seen as an omission given the context. The discussion of epigenetics is fascinating but brief, and the claim that healing can be passed on to future generations is intriguing yet requires more evidence. Overall, the interview is informative and thought-provoking, but viewers should be aware that it represents one expert’s perspective and should seek additional sources for a comprehensive understanding. The title accurately reflects the content, and the interview is well-produced with clear chapter markers. The public comments are largely positive, with many sharing personal experiences and expressing hope for the therapy, though some raise concerns about accessibility and regulatory hurdles.

The title accurately reflects the core message of the interview: Yehuda argues that MDMA-assisted therapy can access emotional and cognitive states that traditional CBT cannot, offering a novel therapeutic avenue for PTSD.

8/10

Rachel Yehuda is a leading PTSD researcher with extensive expertise. The interview is well-structured, covers scientific concepts accurately, and references ongoing clinical trials. However, it is an expert opinion rather than a peer-reviewed presentation, and some claims about MDMA efficacy are based on phase 2/3 trials that have faced regulatory setbacks.

• 00:00Introduction: What trauma does to the brain
• 00:20Chapter 1: Why trauma sticks
• 03:05Stress vs. trauma: what’s the difference?
• 05:55Why most people don’t develop PTSD
• 08:37Chapter 2: How MDMA-assisted therapy can break the loop
• 09:19How trauma warps self-perception
• 12:40MDMA-assisted therapy explained
• 16:38How societal narratives shape recovery (or worsen it)
• 23:04The reality of psychedelic therapy (not a quick fix)
• 28:55Chapter 3: Healing can echo across generations
• 30:48Epigenetics explained
• 40:00Can healing be passed on too?
• 43:43PTSD beyond fear: guilt, shame, and trauma
• 47:01What real healing looks like

• Big Think Membership — Mentioned as a way to support the channel and access exclusive content.
• Full Interview Transcript — Provided in the video description for further reading.
• Up Next: The bizarre phenomena that medicine struggles to explain | David Linden: Full Interview — Suggested as a related video in the description.

• MDMA-assisted therapy for PTSD: A systematic review and meta-analysis — Supports the efficacy of MDMA-assisted therapy for PTSD.
• Epigenetic transmission of trauma — Provides evidence for intergenerational epigenetic effects of trauma.

• FDA rejects MDMA-assisted therapy for PTSD

• bigthinkmedia.substack.com
• open.spotify.com